$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 23 Nov 2016 | 20623 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2016, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 9, 41, 26 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.Ebolavirus Infections (Ebola Hemorrhagic Fever).

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 7

    List of Figures 9

    Introduction 10

    Global Markets Direct Report Coverage 10

    Ebolavirus Infections (Ebola Hemorrhagic Fever) Overview 11

    Therapeutics Development 12

    Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview 12

    Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) - Comparative Analysis 13

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics under Development by Companies 14

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes 18

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Products Glance 19

    Late Stage Products 19

    Clinical Stage Products 20

    Early Stage Products 21

    Unknown Stage Products 22

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Products under Development by Companies 23

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Products under Investigation by Universities/Institutes 28

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development 29

    Abivax SA 29

    AnGes MG Inc 30

    ANP Technologies Inc 31

    Arno Therapeutics Inc 32

    BioCryst Pharmaceuticals Inc 33

    BioFactura Inc 34

    Celgene Corp 35

    Emergent BioSolutions Inc 36

    Enyo Pharma SAS 37

    Etubics Corp 38

    GeoVax Labs Inc 39

    Gilead Sciences Inc 40

    GlaxoSmithKline Plc 41

    Hemispherx Biopharma Inc 42

    Humabs BioMed SA 43

    Immune Response BioPharma Inc 44

    Immunovaccine Inc 45

    Inovio Pharmaceuticals Inc 46

    Integrated BioTherapeutics Inc 47

    Johnson & Johnson 48

    Kineta Inc 49

    Kymab Ltd 50

    Medicago Inc 51

    Merck & Co Inc 52

    Microbiotix Inc 53

    Micropharm Ltd 54

    NanoViricides Inc 55

    Navigen Pharmaceuticals, Inc. 56

    Novavax Inc 57

    Peregrine Pharmaceuticals Inc 58

    Phelix Therapeutics LLC 59

    PlantForm Corp 60

    Profectus BioSciences Inc 61

    RedHill Biopharma Ltd 62

    Regeneron Pharmaceuticals Inc 63

    Rodos BioTarget GmbH 64

    SignPath Pharma Inc 65

    Sirnaomics Inc 66

    Soligenix Inc 67

    Taiga Biotechnologies Inc 68

    Tamir Biotechnology Inc 69

    TGV-Laboratories 70

    Toyama Chemical Co Ltd 71

    Vaxart Inc 72

    XBiotech Inc 73

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment 74

    Assessment by Monotherapy Products 74

    Assessment by Combination Products 75

    Assessment by Target 76

    Assessment by Mechanism of Action 78

    Assessment by Route of Administration 80

    Assessment by Molecule Type 82

    Drug Profiles 84

    (Ebola + Marburg) (monovalent) vaccine - Drug Profile 84

    (Ebola + Marburg) (trivalent) vaccine - Drug Profile 86

    (Ebola + Marburg) vaccine - Drug Profile 88

    (Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile 89

    (Ebola [Sudan] + Marburg) vaccine - Drug Profile 93

    (Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 94

    (REGN-3470 + REGN-3471 + REGN-3479) - Drug Profile 95

    1-E703 - Drug Profile 96

    ABX-544 - Drug Profile 97

    ANP-015 - Drug Profile 98

    Antibodies for Ebola and Marburg Viral Infections - Drug Profile 99

    Antibody for Ebola Viral Infection - Drug Profile 100

    AR-12 - Drug Profile 101

    ARD-5 - Drug Profile 104

    bavituximab - Drug Profile 105

    CC-11050 - Drug Profile 120

    cosfroviximab + larcaviximab + porgaviximab - Drug Profile 121

    DEF-201 - Drug Profile 124

    DLANA-14 - Drug Profile 126

    DPX-Ebola - Drug Profile 127

    Drug for Ebola Virus Infection - Drug Profile 128

    Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile 129

    Ebola (virus like particle) vaccine - Drug Profile 130

    Ebola [Zaire] (monovalent) vaccine - Drug Profile 131

    Ebola [Zaire] vaccine - Drug Profile 133

    Ebola [Zaire] vaccine - Drug Profile 138

    Ebola [Zaire] vaccine - Drug Profile 139

    Ebola [Zaire] vaccine - Drug Profile 140

    Ebola [Zaire] vaccine - Drug Profile 142

    Ebola [Zaire] vaccine - Drug Profile 144

    Ebola [Zaire] vaccine - Drug Profile 145

    Ebola vaccine - Drug Profile 146

    Ebola vaccine - Drug Profile 147

    Ebola vaccine - Drug Profile 148

    Ebola vaccine - Drug Profile 149

    Ebola vaccine - Drug Profile 150

    Ebola vaccine - Drug Profile 151

    Ebola vaccine - Drug Profile 152

    EBOTAb - Drug Profile 153

    favipiravir - Drug Profile 154

    FBH-004 - Drug Profile 157

    FDX-000 - Drug Profile 158

    Fibrinoplate-S - Drug Profile 159

    galidesivir - Drug Profile 160

    Gene Therapy for Ebola Virus Infections - Drug Profile 163

    GOVXE-301 - Drug Profile 164

    GOVXE-302 - Drug Profile 165

    GreEMTri - Drug Profile 166

    GS-5734 - Drug Profile 167

    imatinib mesylate - Drug Profile 168

    ImmunoRx - Drug Profile 169

    INO-4212 - Drug Profile 170

    interferon alfa-
    3 - Drug Profile 172

    IRE-101 - Drug Profile 176

    KIN-1400 - Drug Profile 177

    KV-7005 - Drug Profile 179

    Lalistat - Drug Profile 180

    Lipocurc - Drug Profile 181

    mAb-100 - Drug Profile 183

    mAb-114 - Drug Profile 184

    MB-003 - Drug Profile 185

    MBX-2806 - Drug Profile 186

    MIL-77 - Drug Profile 187

    Monoclonal Antibodies 1 for Ebolavirus Infections - Drug Profile 188

    Monoclonal Antibodies 2 for Ebolavirus Infections - Drug Profile 189

    Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 190

    Monoclonal Antibodies for Ebola Viral Infections - Drug Profile 191

    Monoclonal Antibodies for Viral Infections - Drug Profile 192

    Monoclonal Antibodies to Inhibit Glycoproteins for Ebola Viral Infections - Drug Profile 193

    MonoClonal Antibody for Ebola and Marburg Infections - Drug Profile 194

    Monoclonal Antibody for Ebola Viral Infections - Drug Profile 195

    Monoclonal Antibody for Ebola Viral Infections - Drug Profile 196

    Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile 197

    MV-4 - Drug Profile 198

    NCK-8 - Drug Profile 199

    nilotinib - Drug Profile 200

    OS-2966 - Drug Profile 201

    ranpirnase - Drug Profile 203

    RBT-05 - Drug Profile 206

    Recombinant Protein VSF for Viral Infections - Drug Profile 207

    rintatolimod - Drug Profile 208

    RKP-00156 - Drug Profile 217

    SAB-139 - Drug Profile 218

    Small Molecule 1 for Ebola Viral Infection - Drug Profile 219

    Small Molecule 2 for Ebola Viral Infection - Drug Profile 220

    Small Molecule for Ebola Viral Infection - Drug Profile 221

    Small Molecules for Ebola and Marburg Infections - Drug Profile 222

    Small Molecules for Ebola and Marburg Infections - Drug Profile 223

    Small Molecules for Ebola and Marburg Virus Infections - Drug Profile 224

    Small Molecules for Ebola Viral Infections - Drug Profile 225

    Small Molecules for Ebola Virus Infections - Drug Profile 226

    Small Molecules for Ebolavirus Infections - Drug Profile 227

    Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 228

    Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 229

    Small Molecules to Inhibit NPC1 for Ebola Viral Infections - Drug Profile 230

    Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections - Drug Profile 231

    Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile 232

    STP-802 - Drug Profile 233

    Synthetic Peptides for Ebola Virus - Drug Profile 234

    TMR-004 - Drug Profile 235

    UV-4B - Drug Profile 236

    V-920 - Drug Profile 237

    ZMAb - Drug Profile 242

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects 243

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products 248

    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones 249

    Featured News & Press Releases 249

    Appendix 265

    Methodology 265

    Coverage 265

    Secondary Research 265

    Primary Research 265

    Expert Panel Validation 265

    Contact Us 265

    Disclaimer 266

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

20623 | GMDHC8704IDB

Number of Pages

273

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019SummaryGlobal Markets Dire...
25 Nov 2019 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2018SummaryGlobal Markets Dire...
13 Mar 2018 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2017SummaryGlobal...
31 Jul 2017 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017
Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H1 2017SummaryGlobal Markets Dire...
31 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2016
Ebolavirus Infections (Ebola Hemorrhagic Fever) Global Clinical Trials Review, H2, 2016SummaryGlobal...
30 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...